These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 17537058)

  • 1. Argatroban in extracorporeal membrane oxygenation.
    Beiderlinden M; Treschan T; Görlinger K; Peters J
    Artif Organs; 2007 Jun; 31(6):461-5. PubMed ID: 17537058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Argatroban in adult extracorporeal membrane oxygenation.
    Johnston N; Wait M; Huber L
    J Extra Corpor Technol; 2002 Dec; 34(4):281-4. PubMed ID: 12533066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Argatroban anticoagulation in critically ill patients.
    Beiderlinden M; Treschan TA; Görlinger K; Peters J
    Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study.
    Fisser C; Winkler M; Malfertheiner MV; Philipp A; Foltan M; Lunz D; Zeman F; Maier LS; Lubnow M; Müller T
    Crit Care; 2021 Apr; 25(1):160. PubMed ID: 33910609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration.
    Sin JH; Lopez ND
    J Extra Corpor Technol; 2017 Jun; 49(2):115-120. PubMed ID: 28638161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case series describing the use of argatroban in patients on extracorporeal circulation.
    Cornell T; Wyrick P; Fleming G; Pasko D; Han Y; Custer J; Haft J; Annich G
    ASAIO J; 2007; 53(4):460-3. PubMed ID: 17667231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
    Ansara AJ; Arif S; Warhurst RD
    Ann Pharmacother; 2009 Jan; 43(1):9-18. PubMed ID: 19126826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review.
    Geli J; Capoccia M; Maybauer DM; Maybauer MO
    J Intensive Care Med; 2022 Apr; 37(4):459-471. PubMed ID: 33653194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
    Dager WE; White RH
    Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.
    Matthai WH; Hursting MJ; Lewis BE; Kelton JG
    Thromb Res; 2005; 116(2):121-6. PubMed ID: 15907526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
    Keegan SP; Gallagher EM; Ernst NE; Young EJ; Mueller EW
    Ann Pharmacother; 2009 Jan; 43(1):19-27. PubMed ID: 19116377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of argatroban for extracorporeal life support in patients with nonheparin-induced thrombocytopenia: Analysis of 10 consecutive patients.
    Kim YS; Lee H; Yang JH; Sung K; Suh GY; Chung CR; Yang JH; Cho YH
    Medicine (Baltimore); 2018 Nov; 97(47):e13235. PubMed ID: 30461625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
    Saugel B; Phillip V; Moessmer G; Schmid RM; Huber W
    Crit Care; 2010; 14(3):R90. PubMed ID: 20487559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.
    Hursting MJ; Jang IK
    J Thromb Thrombolysis; 2008 Jun; 25(3):273-9. PubMed ID: 17530465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation with argatroban using hemoclot™ targets is safe and effective in CARDS patients receiving venovenous extracorporeal membrane oxygenation: An exploratory bi-centric cohort study.
    Mayerhöfer T; Joannidis M; Peer A; Perschinka F; Fries D; Mair P; Gasteiger L; Bachler M; Kilo J; Herkner H; Schwameis M; Schellongowski P; Nagler B; Kornfehl A; Staudinger T; Buchtele N
    Thromb Res; 2024 Apr; 236():161-166. PubMed ID: 38452448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.
    Begelman SM; Baghdasarian SB; Singh IM; Militello MA; Hursting MJ; Bartholomew JR
    J Intensive Care Med; 2008; 23(5):313-20. PubMed ID: 18701526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban for anticoagulation in continuous renal replacement therapy.
    Link A; Girndt M; Selejan S; Mathes A; Böhm M; Rensing H
    Crit Care Med; 2009 Jan; 37(1):105-10. PubMed ID: 19050602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.